IVF/ICSI Outcomes After a Freeze-All Strategy: an Observational Cohort Study.
Mathilde BourdonAsim AlwohaibiChloé MaignienLouis MarcellinAhmed CharguiKhaled Pocate CherietCatherine PatratCharles ChapronPietro SantulliPublished in: Reproductive sciences (Thousand Oaks, Calif.) (2023)
In order to inform patients undergoing ART regarding their chances for motherhood, it seems useful to describe "freeze all" outcomes according to the different potential indications. The goal of this study was to examine the impact of a "freeze-all approach" on the cumulative live birth rate (cLBR) according to the indication. It is a cohort study including women who had undergone ovarian stimulation (OS) using an antagonist protocol with GnRH agonist triggering between 09.2016 and 09.2018 followed by a freeze-all cycle of blastocyst embryos. The ART outcomes were compared between the two main indications of the freeze-all strategy which were in our cohort: risk of ovarian hyperstimulation syndrome (OHSS) and endometriosis. The ART outcomes were also described for the others indications (inadequate endometrium and/or premature progesterone elevation at trigger day, two or more previous ART failures, and autoimmune disease and/or a high risk of thromboembolic disease (AI and/or TE risk)). In total, 658 women were included. The cLBR in the total population was 37.7% (248/658). The cLBR was significantly higher in the "OHSS risk" group (133/281, 47.3%) than in the "endometriosis" group (69/190, 36.3%) (p = 0.017). No significant differences were noted regarding perinatal outcomes, except a significantly higher risk of placenta praevia (PP) observed in the "endometriosis" group (10.1%) (p = 0.002). The "freeze-all approach" yielded good results in terms of the cLBR and especially in case of OHSS risk. These data should be taken into account when informing patients about the ART strategy and their chances of motherhood.
Keyphrases
- prognostic factors
- hiv infected
- patients undergoing
- pregnancy outcomes
- antiretroviral therapy
- randomized controlled trial
- polycystic ovary syndrome
- multiple sclerosis
- pregnant women
- type diabetes
- end stage renal disease
- metabolic syndrome
- chronic kidney disease
- electronic health record
- machine learning
- cervical cancer screening
- breast cancer risk
- deep learning
- peritoneal dialysis
- big data
- patient reported